PsyPost
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Neuroscience
  • About
No Result
View All Result
Join
My Account
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Psychedelic Drugs MDMA

MDMA-assisted psychotherapy highly effective in alleviating PTSD symptoms, study finds

by Bianca Setionago
January 9, 2024
Reading Time: 3 mins read
Add as a preferred source on GoogleFollow on Google News

A new study has found that combining the drug MDMA with psychotherapy can help people with moderate to severe post-traumatic stress disorder (PTSD) reduce their symptoms and improve their ability to perform everyday activities. The research, which was conducted as a double-blinded randomized clinical trial, was published in Nature Medicine.

PTSD is a serious mental health condition that affects individuals who have experienced or witnessed a traumatic event, such as violence or natural disasters. Individuals with PTSD may have nightmares, flashbacks, anxiety, depression and difficulty functioning in daily life. Current treatments include psychotherapies (talking therapies that assist people explore their inner thoughts and feelings) in addition to medications, but they have been found to not work for all.

Growing evidence suggests a compound called 3,4-methylenedioxymethamphetamine (more commonly known as MDMA, ecstasy or molly) as a potential treatment. MDMA is a substance that can reduce fear as well as enhance empathy and openness with others. The research team led by Jennifer M. Mitchell from the University of California combined MDMA with psychotherapy, a practice known as MDMA-assisted therapy (MDMA-AT).

The study involved 104 adults recruited from the United States and Israel with moderate to severe PTSD who had not responded to previous treatments. They were randomly assigned to receive either MDMA-assisted therapy (MDMA-AT) (53 participants) or placebo with therapy (51 participants). MDMA-AT consisted of three sessions of MDMA (80–120 mg) with psychotherapy, spaced about 1 month apart, plus 12 sessions of 90-minute therapy (without drug consumption). The placebo with therapy group received identical therapy sessions but instead consumed placebo pills.

Free daily newsletter

Don’t miss the next big psychology finding

Every morning, PsyPost sends a short briefing on the most interesting new peer-reviewed research in psychology and neuroscience.

✓ Free ✓ One email a day ✓ Unsubscribe anytime

The researchers measured the participants’ PTSD symptoms and functional impairment levels before and after the treatment, using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) scale, and Sheehan Disability Scale (SDS), respectively. They found that MDMA-AT significantly reduced PTSD symptoms and functional impairment compared to placebo with therapy.

Mitchell and colleagues also discovered that more participants in the MDMA-AT group achieved clinically meaningful improvement – 86.5% in the MDMA-AT group compared to 69% in the placebo with therapy group. Additionally, 71.2% of participants in the MDMA-AT group were no longer clinically diagnosed with PTSD, compared with 47.6% in the PTSD group. The treatment effect of MDMA was also not influenced by disease severity, trauma type or comorbidities.

The researchers also found that MDMA was generally well tolerated, with no serious or life-threatening events that led to hospitalizations, disability, or deaths. The most common side effects of MDMA were muscle tightness, nausea, decreased appetite and sweating, which were mostly mild or moderate and transient. MDMA caused temporary increases in blood pressure and heart rate, which were expected side effects.

Suicidal ideation was observed in both groups, as is consistent with PTSD symptoms. However, MDMA did not increase the risk of suicidal ideation or behavior, or MDMA abuse or dependence.

Notably, the study included a diverse population of participants with moderate to severe PTSD and various trauma histories and comorbidities. “In a historic first, to our knowledge, for psychedelic treatment studies, participants who identified as ethnically or racially diverse encompassed approximately half of the study sample,” the researchers highlighted, as 26.9% of participants identified as Hispanic/Latino, and 33.7% identified as other than White.

Study author Mitchell emphasized the importance of this inclusivity, “due to disparities in trauma exposure, gender-diverse and transgender individuals, ethnoracial minorities, first responders, military personnel, veterans and victims of chronic sexual abuse have a disproportionately higher risk of developing PTSD. However, these diverse populations are historically underrepresented in clinical trials.”

Some limitations are to be noted. For example, there is a lack of a comparison with other treatments for PTSD, such as selective serotonin reuptake inhibitors (SSRIs). The study also excluded participants with high suicide risk, comorbid personality disorders and underlying cardiovascular disease, which may limit the generalizability of the findings.

Nevertheless, the study was a large, rigorous and confirmatory phase 3 trial that followed FDA guidance, and MDMA-AT could be a promising new treatment for individuals with PTSD who do not respond to current therapies.

The study, “MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial”, was authored by Jennifer M. Mitchell, Marcela Ot’alora G., Bessel van der Kolk, Scott Shannon, Michael Bogenschutz, Yevgeniy Gelfand, Casey Paleos, Christopher R. Nicholas, Sylvestre Quevedo, Brooke Balliett, Scott Hamilton, Michael Mithoefer, Sarah Kleiman, Kelly Parker-Guilbert, Keren Tzarfaty, Charlotte Harrison, Alberdina de Boer, Rick Doblin, Berra Yazar-Klosinski and MAPP2 Study Collaborator Group.

TweetSendScanShareSendPinShareShareShareShareShare

Follow PsyPost

The latest research, however you prefer to read it.

Daily newsletter

One email a day. The newest research, nothing else.

Google News

Get PsyPost stories in your Google News feed.

Add PsyPost to Google News
RSS feed

Use your favorite reader.

Copy RSS URL
Social media
Support independent science journalism

Ad-free reading, full archives, and weekly deep dives for members.

Become a member

Trending

  • Psychedelics trigger a bizarre memory paradox that makes the unknown feel like home
  • Musically trained children score higher on tests of intelligence, working memory, and reading
  • Republicans experience worse mental health in Democratic neighborhoods, study finds
  • New study finds children and teens reason differently about participation trophies
  • Regret is rare among transgender youth who began hormone therapy, according to largest study of its kind

Science of Money

  • What psychology reveals about how founders dial startup obsession up or down
  • New study reveals what actually predicts livestream shopping sales
  • How eating a product today shapes which brand you buy tomorrow
  • The psychology of buying clothes you haven’t seen
  • The hidden social cost of cashierless stores

Recent

  • A 30-minute walk helps sustain brain activity during mental task switching, study finds
  • Scientists finally pin down what a mysterious Alzheimer’s gene does
  • Childhood trauma and ADHD independently fuel risky driving habits, study suggests
  • New psychology study suggests your sexual turn-ons are far more fluid than assumed
  • Past experiences with classical music predict a taste for sophisticated genres
  • The genetic influences on drinking may shift between adolescence and early adulthood
  • Brain damage linked to “pseudopsychopathy” may not reduce the will to empathize
  • New research finds high testosterone does not impair men’s emotional reframing
  • Moderate students self-censor the most on campus, survey finds
  • Brain surface area and cognitive ability may influence each other, genetic study suggests

PsyPost is a psychology and neuroscience news website dedicated to reporting the latest research on human behavior, cognition, and society. (READ MORE...)

  • Mental Health
  • Neuroimaging
  • Personality Psychology
  • Social Psychology
  • Artificial Intelligence
  • Cognitive Science
  • Psychopharmacology
  • Contact us
  • Disclaimer
  • Privacy policy
  • Terms and conditions
  • FAQ
  • Jobs

(c) PsyPost Media Inc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy

(c) PsyPost Media Inc